UK markets closed
NIKKEI 225
27,686.40 -199.47 (-0.72%) HANG SENG
18,814.82 -626.36 (-3.22%) CRUDE OIL
72.16 -2.09 (-2.81%) GOLD FUTURES
1,802.10 +19.70 (+1.11%) DOW
33,513.09 -83.25 (-0.25%) BTC-GBP
13,780.09 -194.50 (-1.39%)
Merck & Co., Inc. (0QAH.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:10PM GMT
| Previous close | 89.51 |
| Open | 92.36 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 89.12 - 89.48 |
| 52-week range | 89.12 - 89.48 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 0.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
RAHWAY, N.J., December 01, 2022--Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
- Business Wire
Merck Announces First-Quarter 2023 Dividend
RAHWAY, N.J., November 29, 2022--Merck Announces First-Quarter 2023 Dividend
- Business Wire
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., November 22, 2022--Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of OS in Patients With HER2-Negative Gastric or GEJ Cancers
© 2022 Yahoo. All rights reserved.
